Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > RxTrials Institute Drug Pipeline Alert > CutiCeuticals Gets Patent for Psoriasis, Eczema Treatment

RxTrials Institute Drug Pipeline Alert

Feb. 8, 2005 | Vol. 3 No. 27

CutiCeuticals Gets Patent for Psoriasis, Eczema Treatment

CutiCeuticals has been granted a patent for its CutiCort Spray.

The product is a .05 percent clobetasol aerosol spray used for the treatment of psoriasis, eczema and other inflammatory skin conditions.

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Pharmaxis Begins Trial of Bronchitol in CF GSK Warns of Label Tampering on HIV Medications CMS Proposes Revised Clinical Trial Policy FDA Extends Review of Neurochem Kiacta Application

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.